Literature DB >> 16883003

Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.

Daniel A Pryma1, Heiko Schöder, Mithat Gönen, Richard J Robbins, Steven M Larson, Henry W D Yeung.   

Abstract

UNLABELLED: Hürthle cell carcinoma is an uncommon and occasionally aggressive differentiated thyroid cancer associated with increased mortality compared with other differentiated thyroid malignancies. Because it generally has lower iodine avidity, 18F-FDG PET has been suggested as a more accurate imaging modality. However, there is limited information with regard to the true diagnostic accuracy and prognostic value of 18F-FDG PET in this disease.
METHODS: All patients with Hürthle cell thyroid cancer who underwent their first 18F-FDG PET scan between May 1996 and February 2003 were identified retrospectively. 18F-FDG PET scans were reviewed and compared with all available imaging studies, including CT, ultrasound, and radioiodine scintigraphy (RIS). Abnormal 18F-FDG uptake was assessed visually and by measuring the maximum standardized uptake value (SUVmax) of the most intense lesion. Clinical follow-up for at least 1 y or until death was required for inclusion.
RESULTS: Forty-four patients met inclusion criteria. The median follow-up was 2.9 y. There were 24 positive and 20 negative 18F-FDG PET scans with 1 false-positive and 1 false-negative study, resulting in a diagnostic sensitivity of 95.8% and a specificity of 95%. In 5 of 11 patients who had both positive CT and 18F-FDG PET findings, 18F-FDG PET revealed additional sites of disease. Furthermore, 18F-FDG PET correctly classified as negative 3 patients with false-positive CT findings. In 3 of 6 patients with positive RIS, 18F-FDG PET revealed additional sites of metastatic disease. Ten patients with positive 18F-FDG PET had negative RIS. Only 1 patient with negative 18F-FDG PET had positive RIS. The SUVmax also provided prognostic information: In a stepwise fashion, each increase in intensity by SUVmax unit was associated with a 6% increase in mortality (P < 0.001). The 5-y overall survival in patients with SUVmax < 10 was 92%; it declined to 64% in those with SUVmax > 10 (P < 0.01).
CONCLUSION: 18F-FDG PET has excellent diagnostic accuracy in Hürthle cell thyroid cancer patients, improving on CT and RIS. Intense 18F-FDG uptake in lesions is an indicator of a poor prognosis. Our data suggest that all patients with Hürthle cell thyroid cancer should undergo 18F-FDG PET as part of their initial postoperative staging and periodically to screen for occult recurrence, particularly in patients with elevated serum thyroglobulin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16883003

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  23 in total

1.  Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.

Authors:  Gustavo S P Meirelles; Heiko Schöder; Gregory C Ravizzini; Mithat Gönen; Josef J Fox; John Humm; Michael J Morris; Howard I Scher; Steven M Larson
Journal:  Clin Cancer Res       Date:  2010-10-25       Impact factor: 12.531

Review 2.  The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview.

Authors:  Giorgio Treglia; Barbara Muoio; Luca Giovanella; Massimo Salvatori
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-02       Impact factor: 2.503

3.  Bilateral Renal Metastasis of Hürthle Cell Thyroid Cancer with Discordant Uptake Between I-131 Sodium Iodide and F-18 FDG.

Authors:  Apichaya Claimon; Minseok Suh; Gi Jeong Cheon; Dong Soo Lee; E Edmund Kim; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2016-12-09

Review 4.  The role of 18F-fluorodeoxyglucose positron emission tomography in thyroid neoplasms.

Authors:  Brian Hung-Hin Lang; Tsz Ting Law
Journal:  Oncologist       Date:  2011-03-04

Review 5.  PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art.

Authors:  Arnoldo Piccardo; Pierpaolo Trimboli; Luca Foppiani; Giorgio Treglia; Giulia Ferrarazzo; Michela Massollo; Gianluca Bottoni; Luca Giovanella
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

6.  Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma.

Authors:  Xuan Canh Nguyen; Won Woo Lee; Amr Mohamed Amin; Jae Seon Eo; Soo-Mee Bang; Jong Seok Lee; Sang Eun Kim
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

7.  Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes.

Authors:  Adolfo Pisanu; Barbara Di Chiara; Isabella Reccia; Alessandro Uccheddu
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

8.  Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.

Authors:  Raj K Gopal; Kirsten Kübler; Sarah E Calvo; Paz Polak; Dimitri Livitz; Daniel Rosebrock; Peter M Sadow; Braidie Campbell; Samuel E Donovan; Salma Amin; Benjamin J Gigliotti; Zenon Grabarek; Julian M Hess; Chip Stewart; Lior Z Braunstein; Peter F Arndt; Scott Mordecai; Angela R Shih; Frances Chaves; Tiannan Zhan; Carrie C Lubitz; Jiwoong Kim; A John Iafrate; Lori Wirth; Sareh Parangi; Ignaty Leshchiner; Gilbert H Daniels; Vamsi K Mootha; Dora Dias-Santagata; Gad Getz; David G McFadden
Journal:  Cancer Cell       Date:  2018-08-13       Impact factor: 31.743

9.  Investigating 18F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review.

Authors:  Hongxi Wang; Hongyuan Dai; Qianrui Li; Guohua Shen; Lei Shi; Rong Tian
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

10.  Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Jatin P Shah; Alvaro Sanabria; Abir Al Ghuzlan; Carl E Silver; Ashok R Shaha; Peter Angelos; Dana M Hartl; Antti A Mäkitie; Kerry D Olsen; Randall P Owen; Gregory W Randolph; Ricard Simó; Ralph P Tufano; Luiz P Kowalski; Mark E Zafereo; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2021-08-22       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.